[Analysis of Long-Term Prognostic Factors Based on Nutritional Status in Patients with Multiple Myeloma].

Objective: To explore the prognostic factors of patients with multiple myeloma (MM) based on nutritional status.

Methods: The Controlling Nutritional Status (CONUT) score and clinical parameters at diagnosis of 203 newly diagnosed MM patients hospitalized in the department of hematology, Wuxi People's Hospital from January 1, 2007 to June 30, 2019 were analyzed retrospectively. The best cut-off value was determined by ROC curve, and the patients were divided into high CONUT group (>6.

[Research Progress on Prognostic Factors of Multiple Myeloma--Review].

At present, multiple myeloma (MM) still can not be cured, so it is particularly important to study the prognostic factors of MM. Recently, based on the characteristics of tumor or host, the complete disease staging systems, such as Mayor mSMART and frailty scoring system have been updated. Other independent prognostic factors, such as minimal residual disease, circulating tumor DNA, red blood cell distribution width, lymphocyte ratio and thymidine kinase 1 are of great value in evaluating the prognosis of MM from different perspectives.

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation.

Purpose: Recently, the British Myeloma Research Alliance put forward a Myeloma Risk Profile (MRP) for the first time to stratify the prognosis risk of non-transplanted patients with multiple myeloma. However, only limited studies have evaluated the applicability of this model in the Chinese population. This study aimed to estimate the prognostic value of MRP in newly diagnosed multiple myeloma patients without autologous stem cell transplantation in China.

Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study.

Introduction: Recently, treatment with proteasome inhibitors and immunomodulators has improved the prognosis of multiple myeloma (MM). However, in a complex real-world situation, the patient's ability to undergo regular and timely treatment as prescribed in clinical trials has not been studied, as well as the impact of extended treatment intervals due to different reasons. This study aimed to evaluate the treatment interval and clinical characteristics of 122 patients with primary myeloma in our hospital and explore the prognostic effects of different treatment intervals.